Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is set for success thanks to strong revenue streams, potential growth from upcoming catalysts, and diversification opportunities from their Technosphere platform and recent acquisition of scPharmaceuticals. Education and marketing initiatives also contribute to the company's growth outlook, with a potential boost from UTHR's confirmation of pursuing Tyvaso DPI for IPF. Risks such as commercial execution, clinical trials, regulatory hurdles, and partnership uncertainties remain, but the company's MNKD-102 product provides a potential backup plan.

Bears say

MannKind is facing significant competition in the diabetes market with its Afrezza product, and the potential success of its other products is uncertain. The company is heavily dependent on its partnerships with other pharmaceutical companies for the commercialization of its products, and its current revenue levels are not sustainable without continued growth and expansion into new markets. Furthermore, MannKind's recent acquisition of scPharmaceuticals adds significant additional financial risk to the company's already unstable financial position. All of these factors contribute to a negative outlook on the company's stock.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.